CUTISS Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 37

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.79M

  • Investors
  • 10

CUTISS General Information

Description

Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company uses patient's cells in combination with a hydrogel to create a dermo-epidermal skin and considerably reduce the need for autografting and further corrective interventions, allowing for considerable savings, enabling patients to get treated from affected skin or damaged skin and achieve a good quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Primary Office
  • Grabenstrasse 11
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

CUTISS Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CUTISS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 17-Jun-2022 $7.79M 000.00 00000 Completed Generating Revenue
8. Accelerator/Incubator 28-Feb-2022 00.000 000.00 Completed Clinical Trials - Phase 1
7. Grant 25-Jan-2022 00000 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC 16-Dec-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 29-Jun-2020 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series A) 27-Jun-2018 000.00 0000 000.00 Completed Clinical Trials - Phase 1
3. Grant 01-Jan-2018 00.000 00.000 Completed Clinical Trials - Phase 1
2. Seed Round 11-Sep-2017 $1.04M $1.04M Completed Clinical Trials - Phase 1
1. Grant 15-Jun-2015 $64.3K Completed Clinical Trials - Phase 1
To view CUTISS’s complete valuation and funding history, request access »

CUTISS Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series A 390,600 $0.102893 $25.72 $25.72 1x $25.72 13.57%
Series A 53,496 $0.102893 $20.58 $20.58 1x $20.58 1.86%
To view CUTISS’s complete cap table history, request access »

CUTISS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company uses patient's cell
Other Healthcare Technology Systems
Schlieren, Switzerland
37 As of 2022
000.00
0000 0000-00-00
0000000000 0 000.00

000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000000000000
Ann Arbor, MI
000 As of 0000
00000
00000000 00000

000000

it amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna ali
000000000000000
Staines-Upon-Thames, United Kingdom
0000 As of 0000
00.00
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CUTISS Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vericel Corporation Ann Arbor, MI 000 00000 00000000 00000
000000000000 Corporation Staines-Upon-Thames, United Kingdom 0000 00.00 0000000000.
You’re viewing 2 of 2 competitors. Get the full list »

CUTISS Patents

CUTISS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021229713-A1 Disposable system and method for preparing a compressed hydrogel Pending 02-Mar-2020 00000000000
CA-3170477-A1 Disposable system and method for preparing a compressed hydrogel Pending 02-Mar-2020 00000000000
AU-2021217829-A1 Cell isolation device and method Pending 06-Feb-2020 00000000000
CA-3168941-A1 Cell isolation device and method Pending 06-Feb-2020 00000000000
AU-2020387177-A1 Methods and systems for producing skin grafts Pending 22-Nov-2019 A61B17/322
To view CUTISS’s complete patent history, request access »

CUTISS Executive Team (8)

Name Title Board Seat Contact Info
Daniela Marino Ph.D Co-Founder, Chief Executive Officer and Board Member
Kathi Mujynya Chief Operation Officer
Fabienne Hartmann-Fritsch Co-Founder & Chief Clinical Officer
Vincent Ronfard Chief Innovation Officer
Ernst Reichmann Ph.D Co-Founder & Board Member
You’re viewing 5 of 8 executive team members. Get the full list »

CUTISS Board Members (6)

Name Representing Role Since
Daniela Marino Ph.D CUTISS Co-Founder, Chief Executive Officer and Board Member 000 0000
Ernst Reichmann Ph.D CUTISS Co-Founder & Board Member 000 0000
Gerard Ber Ph.D Self Board Member 000 0000
Giammaria Giuliani Giuliani Board Member 000 0000
Martin Meuli CUTISS Co-Founder & President of the Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

CUTISS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CUTISS Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Government of France Government 000 0000 000000 0
GISEV Family Office Family Office Minority 000 0000 000000 0
Wyss Zurich Accelerator/Incubator Minority 000 0000 000000 0
Giuliani Corporation Minority 000 0000 000000 0
Yellowstone Holdings Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »